Loading
A phase 3 trial of Divarasib, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06793215 by Hoffmann-La Roche, with 600 participants planned, started 2025-10-24 and due to reach its primary completion in 2028-11-30. Interventions recorded: Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares Pemetrexed, Platinum agents, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Platinum agents, Cisplatin, Carboplatin.